Pharma DECODED
Previous edition: 17 May 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Parallel Bio launches Clinical Trial in a Dish to predict drug efficacy
The Clinical Trial in a Dish approach mirrors the human immune response and patient diversity.
US-based biotech company Parallel Bio has introduced 'Clinical Trial in a Dish' to enhance early-stage drug discovery.
This innovative approach utilises human immune organoids and robotics to simulate the biological diversity of a population, potentially offering more accurate predictions of a drug's safety and efficacy.
Five pharmaceutical companies have already commenced testing 20 drug candidates, signalling a shift away from traditional animal testing.
The Clinical Trial in a Dish approach is designed to mirror the human immune response and patient diversity, which has been a challenge in drug development.
Parallel Bio's testing on over 75 drugs has shown that this method aligns closely with clinical data on the reliability of the immune response and the changes in a drug’s effectiveness based on the individuals.
With drug development costs averaging $2.8bn over ten years and a 95% failure rate in human trials even when they show promise in animals, this technology could be a game-changer.
The new approach is said to be the first application of Parallel Bio's immune system platform, which leverages lymph-node organoids at scale to mimic the human immune system, accommodating the diversity found in real-world populations.
Organoids are 3D models that self-assemble to mimic human biology, responding to disease and treatment as if they were individual patients.
Initial customers are leveraging 'Clinical Trial in a Dish' to evaluate drugs, including their effectiveness across diverse patient profiles and safety prior to human trials.
'Clinical Trial in a Dish' offers several advantages over other non-animal testing methods, as they are scalable, reproducible and diverse.
Parallel Bio co-founder and chief scientific officer Juliana Hilliard said: “By developing drugs in human models from the start, our platform will save $1bn and 6.5 years from each drug candidate in development.
“Our platform aims to flip the 95% drug failure rate into a 95% success rate, leading to more drugs approved to treat patients.”
Latest news
Patient access to medicines must be the focus of US drug pricing policy
Amidst congressional action and changes in payer pricing models, experts discuss what must be done for patients to reap benefits.
FDA grants breakthrough therapy status for Nuvalent's NVL-655
The FDA granted BTD based on the initial data from the Phase I segment of the Phase I/II ALKOVE-1 trial in NSCLC patients.
Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop
The ALS space took another hit after experimental drug BIIB105 failed to show evidence of benefit in patients in the Phase I/II ALSpire trial.
Food Allergy Awareness Week 2024: How can new treatments target an unmet need?
IgGenix is planning to initiate a clinical trial later this year investigating its peanut allergy monoclonal antibody IGXN001.
Roche targets obesity market with early positive trial data
Roche’s GLP-1/GIP receptor agonist, which was gained in the Carmot acquisition, showed an 18.8% weight loss in a Phase Ib trial.
Bayer's non-hormonal therapy reduces hot flashes in Phase III trials
Bayer’s non-hormonal therapy, elinzanetant, reduced the frequency and severity of hot flashes associated with menopause in two Phase III trials.
Eli Lilly's efsitora alfa shows promise in Phase III T2D trials
Once-weekly insulin efsitora alfa offered non-inferior A1C reduction in the QWINT-2 and QWINT-4 trials.
In our previous edition
Pharma Decoded
KRAS inhibitors: The next frontier beckons
16 May 2024
Pharma Decoded
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
15 May 2024
Pharma Decoded
Sanofi to make €1bn biomanufacturing investment in France
14 May 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer